2-Year results from the ample (abatacept versus adalimumab comparison in biologic-naïve RA patients with background methotrexate) trial: Changes in patient-reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis

Category Primary study
ConferenceArthritis and Rheumatism
Year 2013
This article has no abstract
Epistemonikos ID: f56465fd3efc088b18340709ac8925d6772e8eb5
First added on: Apr 30, 2026